Daetwyler Holding AG

Business description

Daetwyler Holding AG is a leading provider of high-quality, system-critical elastomer components. The company serves premium, regulated markets where materials expertise and co-engineering are essential, with a primary focus on Healthcare and Industrial applications.

Key financials

• FY 2025 Revenue: CHF 1,100.5 million (-0.65% YoY).
• Healthcare Revenue: CHF 462.7 million (42% of total, +8.1% organic growth).
• Operating Margin: 12.4% (recovered from previous year).
• Healthcare EBIT Margin: 17.4% (H2 2025).
• Net Income: CHF 80.8 million (FY 2025).

Competitive moat

• System-Critical Components: Produces rubber and elastomer components that are essential for drug delivery and industrial reliability, creating high switching costs.
• Materials Expertise: Deep knowledge in polymer formulations required for highly regulated healthcare and automotive environments.
• Strategic Partnerships: Long-term supply agreements and co-engineering roles with global pharmaceutical and industrial OEMs.
• Regulated Markets: Strong position in segments with high barriers to entry due to stringent quality and regulatory standards (e.g., EU-GMP Annex 1).

Recent developments

• GLP-1 Ramp: Actively scaling capacity to capture massive demand for injectable biologics, particularly GLP-1 (weight loss) therapies.
• Aluminum Capsule Transition: Captured a growing market in single-serve coffee through a majority stake in Capsul'in, pivoting from plastic to aluminum.
• ForwardNow Program: Launched in December 2024 to optimize the operating model and drive medium-term EBIT margins above 17%.

Investment risks / red flags

• Industrial Cyclicality: Sensitivity to the automotive sector (Transportation and Electronics unit) and cautious demand in the Chinese EV market.
• US Market Entry: Execution risk in competing within the US oligopoly for high-value healthcare components.
• Geopolitical Risks: Trade policy uncertainty affecting global manufacturing and supply chains.

H-Score signals

• No data available in the current H-Score dataset.

Theme exposure

• Healthcare Innovation: Critical supplier for injectable drug delivery systems and biologics.
• Electrification: Providing high-performance sealing solutions for EV battery systems and electronics.

Related: [[GLP-1 Supply Chain]] [[Industrial Elastomers]] [[Medical Packaging]]